Dr. Bernard Esquivel – HCS25
CEO, GenXys
Dr. Bernard Esquivel is a Harvard-trained physician-scientist, clinical immunologist, and health tech executive with more than 15 years of experience driving innovation in precision medicine, genomics, and digital health. He is currently the Chief Executive Officer of GenXys, a health technology company specializing in AI-powered platforms that optimize prescribing, improve medication access, and streamline clinical workflows.
Dr. Esquivel received advanced training and specialization from Harvard University in the application of artificial intelligence in healthcare and in regulatory frameworks for prescription drug development and approval. He has served as Chief Medical Officer at leading organizations, including ixlayer, a San Francisco-based health tech platform, and OneOme, a Mayo Clinic subsidiary, and is the founder of Personalized Lifesciences Consulting Inc., advising health tech, biotech, and digital health ventures across global markets.
He serves as Co-Chair of the Global Genomic Medicine Collaborative (G2MC), President and Co-Founder of the Latin American Association of Personalized Medicine (ALAMP), and founding member of the PGRN -Pharmacogenomics Research Network. He is also a Senior Editor for the NIH’s National Center for Biotechnology Information (NCBI) Genetic Summaries Guidelines. Dr. Esquivel sits on multiple boards and serves as a strategic advisor to several health technology organizations around the world. His work continues to focus on translating scientific advances into scalable, patient-centered solutions that improve access, equity, and outcomes across healthcare systems.
Dr. Bernard Esquivel is a Harvard-trained physician-scientist, clinical immunologist, and health tech executive with more than 15 years of experience driving innovation in precision medicine, genomics, and digital health. He is currently the Chief Executive Officer of GenXys, a health technology company specializing in AI-powered platforms that optimize prescribing, improve medication access, and streamline clinical workflows.
Dr. Esquivel received advanced training and specialization from Harvard University in the application of artificial intelligence in healthcare and in regulatory frameworks for prescription drug development and approval. He has served as Chief Medical Officer at leading organizations, including ixlayer, a San Francisco-based health tech platform, and OneOme, a Mayo Clinic subsidiary, and is the founder of Personalized Lifesciences Consulting Inc., advising health tech, biotech, and digital health ventures across global markets.
He serves as Co-Chair of the Global Genomic Medicine Collaborative (G2MC), President and Co-Founder of the Latin American Association of Personalized Medicine (ALAMP), and founding member of the PGRN -Pharmacogenomics Research Network. He is also a Senior Editor for the NIH’s National Center for Biotechnology Information (NCBI) Genetic Summaries Guidelines. Dr. Esquivel sits on multiple boards and serves as a strategic advisor to several health technology organizations around the world. His work continues to focus on translating scientific advances into scalable, patient-centered solutions that improve access, equity, and outcomes across healthcare systems.
